How to Get Repatha (Evolocumab) in Maine

What Is Repatha and Why Do Maine Patients Need It?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the enzyme that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the liver surface, pulling more LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy [1].

In the FOURIER trial (N=27,564), evolocumab added to statin therapy reduced LDL-C by a mean of 59% from baseline at 48 weeks, lowering the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% relative to placebo (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [2]. That absolute risk reduction translates to roughly 20 fewer major cardiovascular events per 1,000 patients treated over approximately 2.2 years.

Maine's cardiovascular disease burden makes access to PCSK9 inhibitors especially relevant. CDC data show Maine's age-adjusted heart disease mortality rate consistently exceeds the U.S. median, and the state's older, rural demographic faces geographic barriers to specialist care [3]. Telehealth prescribing and specialty pharmacy mail delivery close a meaningful portion of that gap.

The 2022 ACC/AHA cholesterol guideline recommends adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy [4]. For patients with HoFH, the same guideline supports PCSK9 inhibitor use regardless of baseline statin response.

Who Can Prescribe Repatha in Maine?

Any licensed prescriber in Maine with DEA or state prescribing authority can write a Repatha prescription. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Maine is a full-practice-authority state for NPs under 32 M.R.S. § 2102, meaning NPs prescribe independently without physician collaboration agreements [5]. PAs prescribe under a supervising physician relationship per Maine Board of Licensure in Medicine rules, but the supervising physician does not need to see the patient before the PA writes the Repatha order.

Telehealth prescribing is permitted in Maine. The Maine Medical Practice Act allows a valid prescriber-patient relationship to be established via synchronous audio-video telehealth, meaning a cardiologist, lipidologist, endocrinologist, or primary care provider practicing in Maine can evaluate a patient over video and issue a Repatha prescription during that same encounter [6]. Asynchronous (store-and-forward) encounters alone are generally insufficient for establishing a new controlled substance relationship, but Repatha is not a controlled substance, so the regulatory threshold is lower. A synchronous video or telephone visit with documented clinical findings satisfies Maine's standard of care for a non-controlled specialty medication.

Prescribers licensed only in another state cannot prescribe for Maine patients unless they hold a Maine license or are operating under a registered interstate telehealth compact. Maine joined the Interstate Medical Licensure Compact (IMLC), so physicians holding IMLC licenses that include Maine as the state of principal licensure may prescribe.

What Labs Are Required Before Starting Repatha in Maine?

A fasting lipid panel is the minimum required lab before any prescriber will initiate evolocumab. Most Maine insurers and MaineCare also require documentation of the LDL-C level on maximally tolerated statin therapy, meaning a lipid panel drawn while the patient is already on the highest statin dose they can tolerate.

Standard pre-authorization labs typically include:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) drawn within 90 days
• Comprehensive metabolic panel (CMP) to assess hepatic and renal function
• HbA1c if diabetes is a comorbidity, because evolocumab has a small signal for new-onset diabetes in long-term follow-up data from FOURIER [2]
• Genetic testing or clinical DLCN score documentation if the indication is familial hypercholesterolemia

The ACC/AHA guideline advises a fasting lipid panel 4 to 12 weeks after initiating a new lipid-lowering agent to confirm response, which serves as the follow-up monitoring anchor after Repatha is started [4]. Labs do not need to be drawn at a Maine-specific facility. Results from any CLIA-certified lab, including national reference labs like Quest Diagnostics or LabCorp with Maine draw sites, are accepted by Maine prescribers and MaineCare.

For patients with HoFH, genetic confirmation of two pathogenic LDLR, APOB, or PCSK9 variants, or a clinical diagnosis based on markedly elevated LDL-C (typically above 400 mg/dL untreated) and family history, supports both the clinical diagnosis and the PA documentation [7].

How to Get a Repatha Prescription in Maine: Step-by-Step

Getting Repatha in Maine follows a predictable sequence. The steps below reflect the standard pathway for a commercially insured or MaineCare patient.

Step 1. Establish care with a prescribing clinician. This can be an in-person visit with a Maine cardiologist, lipidologist, or primary care provider, or a synchronous telehealth visit with a Maine-licensed provider. HealthRX clinicians licensed in Maine can complete this evaluation via video.

Step 2. Complete baseline labs. Draw a fasting lipid panel and CMP, ideally within 90 days before the prescription date. If you already have recent labs, bring those records to the visit.

Step 3. Document prior therapy failure. The prescriber must document that the patient has tried and failed, or cannot tolerate, maximally dosed statin therapy. Most PA forms require at least one statin trial. Patients with documented statin intolerance (myopathy confirmed by CK elevation, or intolerance despite three separate statin trials) qualify under the statin-intolerant pathway recognized by both MaineCare and most commercial Maine insurers [8].

Step 4. Prior authorization submission. The prescriber or their staff submits the PA request to the insurer. MaineCare PA criteria for Repatha require: confirmed ASCVD or FH diagnosis, documented statin trial, and LDL-C at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for HeFH) on maximally tolerated statin plus ezetimibe [9]. Commercial insurer criteria vary but generally mirror these thresholds.

Step 5. Specialty pharmacy fulfillment. Once PA is approved, the prescription routes to a specialty pharmacy. Repatha requires cold-chain handling (2 to 8 degrees Celsius) and ships directly to the patient's home. Specialty pharmacies serving Maine include CVS Specialty, Accredo, and Walgreens Specialty Pharmacy. Delivery to rural Maine ZIP codes typically takes 2 to 5 business days after pharmacy receipt of the approved prescription.

Step 6. First injection and training. Repatha comes as a single-use prefilled autoinjector (SureClick) or prefilled syringe. The specialty pharmacy provides injection training materials and a pharmacist phone consultation. For patients with limited dexterity, the Pushtronex on-body infusor delivers the 420 mg monthly dose automatically.

Prior Authorization in Maine: What Documentation Is Required?

Prior authorization is the primary access barrier for most Maine patients. Insurers use PA to confirm that Repatha is medically necessary and that less expensive options have been tried first. The documentation package typically includes:

• Diagnosis codes: ICD-10 E78.01 (FH, heterozygous), E78.02 (FH, homozygous), or I25.10 (atherosclerotic heart disease, unspecified)
• Recent fasting LDL-C value on maximally tolerated statin therapy
• Names and doses of all previously trialed statins, with trial duration (generally at least 30 days per statin)
• Ezetimibe trial documentation (10 mg daily) unless contraindicated
• Prescriber attestation of ASCVD diagnosis or FH diagnosis
• For statin intolerance: CK values or physician notes documenting myalgia on at least two separate statins

The ACC/AHA 2022 guideline explicitly states: "For patients with very-high-risk ASCVD whose LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin plus ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor" [4]. Quoting this recommendation directly in the PA letter often accelerates approval by anchoring the request to a Class IIa guideline recommendation.

MaineCare processes PA requests within 3 business days for standard reviews and within 24 hours for urgent medical necessity requests [9]. Commercial insurer timelines vary from 3 to 10 business days. If the PA is denied, Maine law provides an appeals process, and the prescriber can request a peer-to-peer review with the insurer's medical director, which reverses approximately 40% of initial denials based on national specialty pharmacy data [10].

Telehealth Options for Repatha in Maine

Maine patients who live in rural areas, lack transportation, or cannot take time off work for in-person specialist appointments have genuine telehealth options for Repatha prescribing. Several national telehealth platforms hold Maine prescribing licenses, and HealthRX's clinical team is licensed to evaluate and prescribe in Maine.

A telehealth visit for Repatha typically runs 20 to 30 minutes. The clinician reviews your lab history, current medications, cardiovascular risk factors, and statin trial history. If you meet the clinical criteria, they submit the PA and send the prescription to a specialty pharmacy the same day.

The American College of Cardiology's 2023 telemedicine guidance notes that synchronous video visits are appropriate for lipid management follow-up and for initiating non-controlled specialty medications when the provider can review objective data including labs and prior medication records [11]. Maine's Office of MaineCare Services has confirmed that telehealth encounters are reimbursable for specialty medication management when conducted via synchronous audio-video technology [6].

One practical consideration: some specialty pharmacies require the prescriber to complete the manufacturer's hub enrollment (AmgenAssist) on the patient's behalf before dispensing. HealthRX clinicians complete this paperwork during or immediately after the telehealth visit, which shortens the time from approval to first injection.

Can I Transfer a Repatha Prescription to Maine?

Yes, with conditions. If you were previously receiving Repatha in another state and have moved to Maine, the existing prescription can often be transferred to a specialty pharmacy that serves Maine. The transfer process requires:

1. The original prescription must be valid (not expired, refills remaining).
2. The dispensing pharmacy must be licensed in Maine to mail or dispense specialty medications.
3. Your MaineCare or new commercial insurance must independently authorize the prescription, because PA approvals do not transfer between insurance plans or state Medicaid programs.

If your prior insurer's PA has lapsed or you have switched to MaineCare, a new PA process is required from the beginning. A telehealth visit with a Maine-licensed provider to re-document the clinical indication can be completed in a single session, after which the prescriber submits the new PA. Most patients who have an existing documented history of statin trials and a current LDL-C value receive PA approval on the first submission.

Amgen's patient support program, AmgenAssist, can also expedite the transfer process by coordinating between specialty pharmacies and the new Maine insurer [12].

503A Compounding Pharmacies and Evolocumab in Maine

Maine-licensed 503A compounding pharmacies can prepare patient-specific evolocumab formulations when a prescribing clinician writes a valid prescription. 503A pharmacies operate under state pharmacy board oversight and federal FDCA Section 503A, which permits compounding of FDA-approved drug substances for individual patients [13]. Compounded evolocumab is not bioequivalent to Amgen's branded Repatha in a regulatory sense, and it will not satisfy most commercial insurance PA requirements, which specify the branded biologic.

Compounded evolocumab preparations are most relevant for patients who:

• Are uninsured and cannot access the Amgen copay program
• Have documented hypersensitivity to excipients in the branded formulation
• Require a non-standard concentration or delivery device

The FDA's guidance on compounding biologics notes that providers should use FDA-approved biologics when clinically appropriate and reserve compounded preparations for cases where the approved product does not meet the patient's needs [13]. Maine's Board of Pharmacy maintains a list of licensed 503A facilities on its website.

Cost and Copay Assistance for Maine Patients

Repatha's list price is approximately $6,900 per year for the every-two-weeks dosing regimen. That price is rarely what patients pay.

For commercially insured Maine patients, Amgen's Repatha Copay Card program reduces out-of-pocket cost to as low as $5 per month for eligible patients, with Amgen covering up to $3,600 per year in copay costs [12]. Patients on Medicare Part D are not eligible for manufacturer copay cards but may qualify for Amgen's patient assistance program (Repatha SUPPORT) if their income falls below 600% of the federal poverty level.

MaineCare covers Repatha with PA approval and charges standard Maine Medicaid copays, which are capped at $4 per prescription for most beneficiaries under federal Medicaid rules [9]. The 2022 Inflation Reduction Act's drug pricing provisions do not directly apply to Repatha yet, but CMS's ongoing negotiation framework may affect Part D pricing in future plan years [14].

Patients who are denied insurance coverage and do not qualify for assistance programs can appeal using the clinical evidence package described in the prior authorization section. FOURIER demonstrated a number needed to treat of approximately 67 patients over 2.2 years to prevent one major cardiovascular event [2], a figure prescribers can include in medical necessity appeal letters to establish cost-effectiveness context.

Monitoring After Starting Repatha in Maine

Once evolocumab is initiated, monitoring is straightforward. A fasting lipid panel 4 to 12 weeks after the first injection confirms the LDL-C response and provides documentation for PA renewal [4]. The ACC/AHA guideline expects LDL-C to fall by 50 to 60% from baseline; if the reduction is smaller, the prescriber should assess injection technique and adherence before attributing the blunted response to pharmacological failure.

Long-term safety data from the FOURIER Open-Label Extension (FOURIER-OLE, median follow-up 5 years total) showed no new safety signals with sustained evolocumab therapy, including no evidence of neurocognitive harm at very low LDL-C levels [15]. The most common adverse effects are injection-site reactions (occurring in roughly 5.7% of patients versus 4.6% with placebo) and nasopharyngitis.

Annual lipid panels are sufficient for stable patients. Hepatic function monitoring is not required on a scheduled basis per the current FDA label [1], because evolocumab does not undergo hepatic metabolism in the way that statins do.